Join the Benralizumab group to help and get support from people like you.
Benralizumab News
Benralizumab Beneficial for Eosinophilic Exacerbations of Asthma, COPD
TUESDAY, Dec. 10, 2024 – Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published...
Scientists Develop Whole New Form of Effective Asthma Treatment
THURSDAY, Nov. 28, 2024 – Geoffrey Pointing says its hard to describe the distress of an asthma or COPD flare-up. “Honestly, when you're having a flare up, it's very difficult to tell anybody how y...
Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis
18 September 2024 – AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, im...
Histologic Response Up With Benralizumab for Eosinophilic Esophagitis
WEDNESDAY, June 26, 2024 – Benralizumab yields a greater histologic response than placebo for patients with eosinophilic esophagitis, but does not affect dysphagia symptoms, according to a study...
Fasenra Approved for Treatment of Children Aged 6 to 11 with Severe Asthma
WILMINGTON, Del.--(BUSINESS WIRE) April 11, 2024 --AstraZeneca’s Fasenra® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients wi...
FDA Approves Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration
October 4, 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector...
FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma
November 14, 2017 – AstraZeneca (NYSE:AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra...